Compare OSIS & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSIS | LGND |
|---|---|---|
| Founded | 1987 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.7B |
| IPO Year | 1997 | 1997 |
| Metric | OSIS | LGND |
|---|---|---|
| Price | $204.47 | $285.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $302.83 | $256.29 |
| AVG Volume (30 Days) | ★ 231.4K | 200.4K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.76 | ★ 2886.36 |
| EPS | ★ 8.95 | 1.63 |
| Revenue | ★ $1,089,286,000.00 | $141,102,000.00 |
| Revenue This Year | $9.74 | $1.25 |
| Revenue Next Year | $5.53 | $19.41 |
| P/E Ratio | ★ $22.80 | $171.89 |
| Revenue Growth | 13.35 | ★ 29.48 |
| 52 Week Low | $186.50 | $158.52 |
| 52 Week High | $311.72 | $326.63 |
| Indicator | OSIS | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 37.97 | 46.17 |
| Support Level | $204.34 | $181.43 |
| Resistance Level | $227.72 | $322.06 |
| Average True Range (ATR) | 8.18 | 9.65 |
| MACD | -3.09 | -1.43 |
| Stochastic Oscillator | 39.47 | 17.33 |
OSI Systems Inc is a designer and manufacturer of electronic systems and components for businesses in the homeland security, healthcare, defense, and aerospace markets. The firm is organized in three business segments: Security, which derives maximum revenue, provides security and inspection systems; Healthcare, which provides patient monitoring, diagnostic, cardiology, ventilation systems, and defibrillators; and Optoelectronics and Manufacturing, which provides specialized electronic components and manufacturing services for the Security and Healthcare segments and external original equipment manufacturers. The majority of the firm's revenue is generated in the United States, and the rest from Mexico, Europe, the Middle East and Africa, and the Asia Pacific regions.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.